Semaglutide vs. Tirzepatide: What the 2026 Data Actually Says

People talk about semaglutide and tirzepatide like they are the same thing. They are not.

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are both GLP-1 medications, but they work through different receptors, they have different evidence behind them, and depending on what you actually care about, they have meaningfully different strengths.

The SURMOUNT-5 trial, the first randomized head-to-head comparison ever run, was published in the New England Journal of Medicine in May 2025. It settled the weight loss question. The rest of the picture is more interesting than the headline number, and the nuance matters if you are choosing between them.

How they work

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that tells your brain you are full, slows how fast your stomach empties, and steadies blood sugar. One target, one mechanism.

Tirzepatide is a dual agonist. It hits GLP-1 receptors and GIP receptors at the same time. GIP, short for glucose-dependent insulinotropic polypeptide, was long assumed to be mostly irrelevant to obesity. Tirzepatide's developers bet that co-activating it would produce a synergistic effect, and the data has backed them up.

The GIP receptor's role in fat tissue looks especially important. GIP receptors in fat cells help regulate lipid uptake and storage, and when they are activated alongside GLP-1 receptors, the combined effect on fat mobilization and energy expenditure is larger than either one alone. That is the mechanistic reason tirzepatide consistently outperforms semaglutide on weight.

What SURMOUNT-5 found

Phase 3b, open-label, randomized. 751 adults with obesity and no type 2 diabetes, each on the maximum tolerated dose of their assigned drug. The primary endpoint was percent change in body weight at 72 weeks.

• Tirzepatide: 20.2 percent average body weight loss
• Semaglutide: 13.7 percent average body weight loss
• p less than 0.001

Tirzepatide patients were also more likely to hit the 10 percent, 15 percent, and 20 percent weight loss thresholds.

What happens outside a clinical trial

Trials run under tightly controlled conditions with motivated, closely monitored participants. Real-world numbers usually look worse. Here they held up.

A large US database study using the Truveta dataset, published in early 2026, found that real-world rates of losing at least 15 percent of body weight at 12 months were 42 percent for tirzepatide versus 18 percent for semaglutide. The gap survived contact with real life, which is notable.

A 2026 meta-analysis in Obesity Research and Clinical Practice pooled 12 studies and found tirzepatide produced significantly greater percentage weight reduction across both randomized trials and real-world cohorts, with a mean difference of 4.61 percent and p less than 0.00001. The advantage was dose and duration dependent. It showed up most clearly above 10mg and after more than six months of treatment.

One number cuts across both drugs and deserves attention: discontinuation rates were roughly 55 percent for both medications within a year. Adherence, not pharmacology, may be the single biggest determinant of your outcome. The best medication is the one you actually stay on.

Where semaglutide has the stronger case

Tirzepatide wins on weight loss. That part is not close. The story branches when you bring cardiovascular outcomes into it.

The SELECT trial enrolled more than 17,000 participants and showed a 20 percent reduction in major adverse cardiovascular events in overweight and obese adults who had existing cardiovascular disease but not type 2 diabetes. That data led directly to FDA approval of Wegovy for cardiovascular risk reduction in March 2024.

Then there is the STEER study, a retrospective propensity-matched cohort published in early 2026 that analyzed more than 10,000 matched patients per arm, all with established atherosclerotic cardiovascular disease and no diabetes. Semaglutide was associated with a 29 percent lower risk of 3-point MACE compared with tirzepatide, with a hazard ratio of 0.71 and p equal to 0.046. The authors suggested this may be specific to semaglutide's selective GLP-1 agonism rather than a shared class effect. Tirzepatide's own cardiovascular outcomes data, from SURPASS-CVOT and TRIUMPH, is still coming in.

So the practical read is this. If your primary goal is maximum weight loss, tirzepatide has the better data. If your primary goal is lowering cardiovascular event risk, especially with established heart disease, semaglutide's evidence base is currently stronger.

The right question is not which drug is better. It is which drug is better for what you are trying to do.

Side effects: similar, with one real difference

Both drugs cause mostly gastrointestinal effects. Nausea, vomiting, diarrhea, constipation, usually worst during dose escalation. For most people these are mild to moderate and fade substantially as the body adjusts.

SURMOUNT-5 did surface one meaningful tolerability difference. Tirzepatide had a lower discontinuation rate due to adverse effects, 2.7 percent versus 5.6 percent for semaglutide. That is roughly half the dropout rate, which matters when adherence drives long-term results.

Both carry a boxed warning about thyroid C-cell tumors, based on rodent data with unestablished significance in humans. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN2.

The oral option

Novo Nordisk received FDA approval for oral Wegovy tablets in December 2025. Research published in September 2025 showed oral semaglutide produced mean weight loss of 13.6 percent, essentially matching the injectable and still below tirzepatide, but it removes the needle entirely for people who would rather not self-inject. There is no oral tirzepatide as of mid-2026.

Cost and access

Insurance coverage for both remains inconsistent and is changing quickly. Medicare and some Medicaid plans are expected to begin covering incretin-based weight loss drugs during 2026, which would meaningfully change access. Both Novo Nordisk and Eli Lilly run savings programs for commercially insured patients without coverage.

Without insurance the two are priced similarly. Compounded versions, prepared by licensed compounding pharmacies and not FDA approved, generally start around 99 to 125 dollars per month depending on dose and provider.